Prospective surveillance study in a 1,400‐bed university hospital: COVID‐19 exposure at home was the main risk factor for SARS‐CoV‐2 point seroprevalence among hospital staff
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.09.29.20203737: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The study protocol was approved by the local ethics committee of the Friedrich-Schiller-University Jena (approval no. 2020-1774) and the study was registered at the German Clinical Trials Register (DRKS00022432).
Consent: Employees were included if they signed a written informed consent form, answered a questionnaire (see below) and agreed on providing a blood sample (not exceeding 9 ml of venous blood).Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources SARS-CoV-2 antibody testing: Presence of SARS CoV-2 antibodies was investigated by two different … SciScore for 10.1101/2020.09.29.20203737: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The study protocol was approved by the local ethics committee of the Friedrich-Schiller-University Jena (approval no. 2020-1774) and the study was registered at the German Clinical Trials Register (DRKS00022432).
Consent: Employees were included if they signed a written informed consent form, answered a questionnaire (see below) and agreed on providing a blood sample (not exceeding 9 ml of venous blood).Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources SARS-CoV-2 antibody testing: Presence of SARS CoV-2 antibodies was investigated by two different commercially available IgG detecting immunoassays: an enzyme-linked immunosorbent assay EDI Novel Coronavirus SARS-CoV-2 IgG ELISA (Epitope Diagnostics Inc., San Diego, USA) and a chemiluminescence-based immunoassay Elecsys Anti-SARS-CoV-2 (Roche, Basel, Switzerland). Anti-SARS-CoV-2suggested: NoneSoftware and Algorithms Sentences Resources Clopper-Pearson CIs were calculated with Microsoft Excel 2016. Microsoft Excelsuggested: (Microsoft Excel, RRID:SCR_016137)All other analyses were done with SPSS Statistics version 25.0 for Windows (IBM Corp., Armonk, NY, USA). SPSSsuggested: (SPSS, RRID:SCR_002865)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:This study has the following limitations: Despite the high number of participants, the recruitment rate was below 10% of the total JUH staff and results of previous COVID-19 testing and compliance using PPE were only recorded by self-reports. We determined antibody titres repeatedly only in those with discrepant results. As SARS-CoV-2 infection generates two waves of antibodies, the provided data do not reflect long-lived immunity [34].
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
